SABCS 2024 – Lilly's PI3Kα push is no longer mutation-specific
Lilly sheds more light on its second PI3Kα take, as Relay's combo data improve.
Another pan-KRAS project enters the clinic
Quanta now has a “G12V-preferring” multi-KRAS asset on its clinical roster.
SABCS 2024 – Ember-3 dims hopes for Lilly’s SERD
Imlunestrant monotherapy only works in ESR1 mutants, but a Verzenio combo is better in all-comers.
ASH 2024 – Jaypirca's confirmation, despite no survival
Crossover scuppers Jaypirca's survival benefit, but full approval seems likely.
ASH 2024 – AstraZeneca aims to fix Calquence’s position
But with Brukinsa and degraders looming, will fixed dosing make the difference?
ASH 2024 – CellCentric's myeloma first
Inobrodib's first substantial multiple myeloma dataset suggests late-line promise.
ASH 2024 – Sumitomo joins the menin party
Enzomenib might be the most promising agent so far, on a cross-trial basis.
